• Home
  • About
  • Leadership
  • Technology
  • Pipeline
  • News
  • Careers
  • Contact

Recent Posts

  • Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis
  • Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting
  • Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting
  • Artiva Biotherapeutics Receives FDA Fast Track Designation for AB-101
  • Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting

Archives

  • August 2023
  • May 2023
  • April 2023
  • January 2023
  • November 2022
  • October 2022
  • September 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • January 2022
  • October 2021
  • September 2021
  • August 2021
  • May 2021
  • April 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • June 2020

Categories

  • Press Releases

Archives

  • August 2023
  • May 2023
  • April 2023
  • January 2023
  • November 2022
  • October 2022
  • September 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • January 2022
  • October 2021
  • September 2021
  • August 2021
  • May 2021
  • April 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • June 2020

Category: Executives

Fred Aslan, M.D.

Jennifer Bush

Peter Flynn, Ph.D.

Thorsten Graef, M.D., Ph.D.

Christopher Horan

Eugene Helsel

John Lim, Pharm.D.

Heather Raymon, Ph.D.

  • Privacy Policy
  • Terms

© Artiva Biotherapeutics, Inc., 2023

Sign up for news updates


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.AcceptPrivacy Policy